Cytotoxic T-cell activation profile in critically ill children with malignancies and hemophagocytic lymphohistiocytosis

Cytotoxic T-cell activation profile in critically ill children with malignancies and hemophagocytic lymphohistiocytosis

Introduction

Hemophagocytic lymphohistiocytosis (HLH) is a rapidly progressive and highly fatal disease with a mortality rate of more than 30% in pediatric patients.1,2 According to Histiocyte Society’s HLH-2004 criteria, a clinical diagnosis of HLH can be made by fulfilling five out of eight clinical features, including fever, cytopenia, splenomegaly, hypertriglyceridemia or hypofibrinogenemia, hemophagocytosis, NK cell dysfunction, and elevated levels of ferritin and soluble IL-2 receptor (sIL-2R).3 Because of immune dysregulation associated with primary malignancy, malignancy-associated treatment, or comorbid severe infection, HLH-like symptoms are not uncommon in critically ill children with malignancies, making their early diagnosis of malignancy-associated HLH (M-HLH) quite challenging, and the estimated 1-year overall survival rate of adults and children is less than 40%.4,5 Searching for early sensitive and specific biomarkers in the diagnosis of HLH is imperative for critically ill children with malignancies.

The pathophysiology of HLH is based on the persistent activation of T cells and macrophages, inducing severe inflammatory response with multiple organ dysfunction and even death, and uncontrolled T-cell activation and secreted interferon-gamma (IFN-γ) are the key drivers of HLH.6 In routine laboratory tests, high levels of sIL-2R and ferritin have been used for the diagnosis of M-HLH.7 Nevertheless, both indexes lack specificity in patients, limiting their use in the context of early intervention.

CD38 is a type II transmembrane immunomodulatory protein expressed on thymocytes and different immune cells.8 Co-expression of CD38 and HLA-DR on CD8 + T cells is the hallmark of cytotoxic T-cell activation, which expresses genes involved in cell proliferation, glycolysis, and cytotoxicity; tends to polarize Tc1 cells; and secretes IFN-γ and tumor necrosis factor in response to external stimuli.9,10 Recently, the frequency of CD38 + HLA-DR + T cells in CD8 + T cells (CD38 + HLA-DR + CD8 + T cells%) was reported to exhibit potential application value in the differentiation of HLH from early sepsis in children,9 however, its early diagnostic value to identify the HLH in a relatively large cohort of critical children with malignacies is still unknown.

This study aims to present the value of cytotoxic T-cell activation profile (CD38 + HLA-DR + CD8 + T cells% and IFN-γ) in the early diagnosis of M-HLH in critically ill children.

Methods

Population

This retrospective observational study in a tertiary children’s medical center was approved by the Institutional Review Board (No. SCMCIRB-K2024117-1). From December 2022 to July 2024, critically ill children with malignancies who were transferred to the pediatric intensive care unit and suffered from persistent two- or three-line cytopenia (persistent for at least 3 days) were enrolled. The patients were divided into two groups based on how many HLH-2004 criteria they fulfilled: M-HLH group, ≥5 criteria; hematologic malignancy (HM) group, ≤4 criteria. In the absence of an NK activity test, more than six criteria were required to be fulfilled. Children treated with chimeric antigen receptor T-cell immunotherapy or hematopoietic stem cell transplantation were excluded. Cell activation indexes such as CD38 + HLA-DR + CD8+ T cells% (gated on CD8+ T cells; Fig. 1a, b), CD14 + HLA-DR+ monocytes% (gated on CD14+ monocytes), and IFN-γ were tested by flow cytometry using peripheral blood samples within 24 h of patient’s admission. The Pediatric Sequential Organ Failure Assessment (pSOFA) and the Pediatric Risk of Mortality (PRISM) III score were used for clinical severity evaluation.11,12 Sepsis was diagnosed using the following criterion: infection with pSOFA score ≥ 2.

Fig. 1: Peripheral blood cell activation profile and inflammation indexes.
Cytotoxic T-cell activation profile in critically ill children with malignancies and hemophagocytic lymphohistiocytosis

a Representative Flow cytometry plots of CD38 + HLA-DR + CD8+ T cells in M-HLH (a) and HM (b) groups. ch Comparison of CD38 + HLA-DR + CD8+ T cells%, IFNγ, CD14+HLA-DR+ monocyte%, sIL-2R, Ferritin, and LDH in patients of the two groups. LDH lactate dehyrogenase. Independent-samples Mann–Whitney U test was used for the comparison of two groups, Bars represent the median and interquartile range, ※indicates p < 0.05.

Full size image

Statistical analysis

IBM SPSS Statistics (Version 27) and GraphPad Prism 10 (Version 10.2.0) were used for data analysis or graph plotting. Independent-samples Mann–Whitney U test was used to compare the differences in indexes between groups depending on whether the data conform to a Gaussian distribution. Receiver operating characteristic (ROC) analysis was used to test the efficacy of cytotoxic T-cell activation indexes to differentiate pediatric M-HLH from HM. Pearson’s correlation was used to detect the correlation between cytotoxic T-cell activation indexes and clinical severity scores.

Results

General characteristics of patients

A total of 64 critically ill children with malignancies and cytopenia were enrolled, of which nine patients underwent chimeric antigen receptor T-cell immunotherapy therapy, 10 patients had hematopoietic stem cell transplantation, and eight children who did not complete more than six tests of HLH diagnostic criteria were excluded. The data of 37 patients were finally used for analysis. Twenty children were classified into the M-HLH group, with primary diseases including 10 cases of leukemia, 4 cases of lymphoma, and 6 cases of post-transplantation lymphoproliferative disorder. Seventeen children were classified into the HM group, with primary diseases including 14 cases of leukemia, 2 cases of lymphoma, and 1 case of idiopathic thrombocytopenic purpura. Bone marrow examinations were conducted in 18 patients from the M-HLH group and 15 patients from the HM group, with hemophagocytosis confirmed in only 3 cases within the M-HLH group. There was no statistically significant difference between the age and weight of the two groups (Table 1).

Table 1 General characteristics of patients
Full size table

The percentages of comorbid sepsis in the two groups were 75% (M-HLH) and 29.4% (HM). In the M-HLH group, 73.3% were infected with bacteria, and 46.7% had viral infections, mainly Epstein-Barr Virus (EBV) (5/7, 71.4%). Approximately 60% of the patients were treated with low-dose dexamethasone (0.1–0.5 mg/kg) or methylprednisolone (1–2 mg/kg) per day and 40% with high-dose glucocorticoids (methylprednisolone 10–20 mg/kg per day) to control the excessive inflammatory response within the first 48 h (Table 1).

Peripheral blood cell activity profile and inflammation indexes

The values of CD38 + HLA-DR + CD8+ T cells%, IFN-γ, and ferritin were higher in the M-HLH group than in the HM group. Neither CD14 + HLA-DR+ monocytes% nor sIL-2R or lactate dehyrogenase (LDH) exhibited statistically significant differences among children between the two groups. The median values of CD14 + HLA-DR+ monocytes% in the M-HLH and HM groups were 92.53% and 90.63%, respectively (Table 1, Fig. 1c–h).

ROC analysis indicated that the area under the curve values (AUC) of CD38+HLA-DR + CD8+ T cells%, IFN-γ, and ferritin were 0.906, 0.897, and 0.693, respectively (Fig. 2); AUC of the combined parameter: predicted probability calculated by binary logistic regression with CD38 + HLA-DR + CD8+ T cells (%) and INFγ was 0.906 (p < 0.01). The sensitivity and specificity of CD38+/HLA-DR + CD8+T cells% > 39.66% to differentiate critically ill children with M-HLH from those with HM were 85.0% and 88.2%, respectively; the sensitivity and specificity of IFN-γ > 22.58 to differentiate the two groups of children were 85% and 94%, respectively.

Fig. 2: The ROC of T-cell activation profile and Ferritin in distinguishing cases of M-HLH from HM.
figure 2

a ROC curves of CD38 + HLA-DR + CD8+ T cells as a percentage of CD8+ T cells (AUC = 0.906, p < 0.01), IFNγ (AUC = 0.897, p < 0.01) and Ferritin (AUC = 0.693, p = 0.046). b ROC curve of the combined parameter: Predicted probability calculated by binary logistic regression with CD38 + HLA-DR + CD8+ T cells (%) and IFNγ (AUC = 0.906, p < 0.01).

Full size image

Severity scores and prognosis

Children in the M-HLH group demonstrated significantly higher pSOFA score compared to those in the HM group, however, the Pediatric Risk of Mortality III (PRISM III) score did not differ significantly between the two groups. (Fig. 3a, Table 1). Further analysis of pSOFA evaluation indicated that in the M-HLH group, the most frequently involved organ systems were the cardiovascular, coagulation, and respiratory systems (Fig. 3b). There were seven deaths in the M-HLH group and two deaths in the HM group.

Fig. 3: The clinical severity parameters and details of multiple organ dysfunction in patients.
figure 3

a Comparison of pSOFA and PRISM III score in patients of the two groups. Bars represent the median and interquartile range. b Heatmap of pSOFA score details of the patients. Gray scale of the bar represents the pSOFA score value. pSOFA Pediatric Sequential Organ Failure Assessment. PRISM Pediatric Risk of Mortality.

Full size image

No statistically significant correlation was observed between severity scores and cytotoxic T-cell activation indices in pediatric patients within the M-HLH group (Table 2).

Table 2 Correlation of Cytotoxic T-cell activation indexes with severity scores in M-HLH group
Full size table

Discussion

Early intervention in the hyperinflammatory state is critical for reversing multiple organ failures and reducing mortality in children with malignancy-associated HLH. This approach not only helps to lower ICU costs but also, more importantly, enhances opportunities for subsequent treatment of the underlying disease. However, effective intervention relies on early identification, which remains a significant challenge for intensivists. This study investigated the T-cell activation profile in a cohort of critically ill children with malignancies. We demonstrated that CD38 + HLA-DR + CD8+ T cells% and IFN-γ are beneficial for the early identification of children with M-HLH. In contrast, neither the macrophage activation index nor other commonly used indicators of HLH exhibit the same capacity.

Critically ill children with malignancies usually suffer from complex immune disorders induced by the primary cancer type, chemical therapy, and pathogen infection,13 the diagnosis of HLH depending on clinical features and traditional tests often fails to fulfill the requirement of early identification.5 Considering the crucial function of T-cell activation in the immune response, it is important to monitor this profile in suspected cases.6

CD38 + HLA-DR + CD8+ T cells%, one of the T-cell activation indexes, has been detected in various diseases related to the initiation of adaptive immunity. In viral infections such as SARS-CoV-2, dengue, Ebola, EBV, and Cytomegalovirus, both CD38 and HLA-DR were highly expressed on CD8+ T cells in patients, and the prolonged activation of CD8+ T cells may correlate with disease severity and poor outcomes.14,15,16,17 In 2021, Chaturvedi et al. found significantly elevated levels of CD38 + HLA-DR + CD8+ T cells in the peripheral blood and organs of children with HLH, suggesting for the first time that this index could be used as an important diagnostic parameter to differentiate HLH from early sepsis.9 This finding was also confirmed in a report of children with HLH caused by visceral leishmaniasis.18 In contrast with other types of hyperinflammatory diseases such as multisystem inflammatory syndrome in children, Kawasaki disease, Still’s disease, adenovirus, SARS-CoV-2, or parainfluenza infections, a more severe systemic inflammatory response was demonstrated in HLH or macrophage activation syndrome with a higher level of CD38 + HLA-DR + CD8+ T cells% in children.10,19 Compared with T cells, the macrophage activation subset (CD14 + HLA-DR+ monocytes%) exhibited markedly elevated values in both groups. The function of macrophages in malignancies is complicated because macrophages are involved in the chronic inflammatory process and also play a role in the modulation of cancer development, which may limit their application in differentiating HLH in children with malignancies.20

Aside from CD38 + HLA-DR + CD8+ T cells%, IFN-γ was another key index of T-cell activation in this study. Similar to our results, the value of IFN-γ in identifying pediatric HLH has also been proved in previous research.21,22 Interestingly, although IFN-γ is a downstream cytokine following T-cell activation, it did not always increase in parallel with CD38 + HLA-DR + CD8+ T cells%, and the cutoff value of our research was relatively low. This contradictory finding may be related to the early use of glucocorticoids, which inhibited the IFN-γ signaling pathway in activated T cells and other IFN-γ-secreting cell subpopulations.23

While the T-cell activation profile demonstrates potential for early detection of M-HLH, its lack of correlation with clinical severity scores warrants further exploration. Three key factors may explain this finding. First, in critically ill pediatric malignancy patients, organ failure may arise from diverse mechanisms, including tumor infiltration, chemotherapy/radiotherapy toxicity, or opportunistic infections, which could overshadow immune-mediated contributions. Second, emerging evidence suggests that coagulation abnormalities in sepsis may drive organ dysfunction beyond immune activation.24 Finally, immune profiling was limited to peripheral blood, which may not fully capture tissue-specific inflammatory processes in affected organs. Therefore, the immunological biomarkers must be applied judiciously when predicting outcomes in critically ill pediatric malignancy patients.

The major limitation of this study is the heterogeneity of our patients’ diseases, which resulted in a high dispersion of the data. However, regardless of the etiological factor, uncontrolled T-cell activation is a common pathway for the progression of HLH. The significance of monitoring the biomarkers in clinical practice is to provide timely evidence for early intervention. Another key limitation lies in the retrospective nature of this study. Variations in steroid regimens and incomplete follow-up data further hindered our capacity to assess dynamic changes in T-cell activation profile. Future prospective studies with larger cohorts are warranted to comprehensively characterize immune dysregulation in children with specific malignancies and to evaluate the clinical utility of T-cell activation biomarkers in guiding therapeutic strategies.

In conclusion, cytotoxic T-cell activation profile with CD38 + HLA-DR + CD8+ T cells% and IFN-γ is valuable in the early diagnosis of M-HLH in critically ill children.

Related Articles

Iron homeostasis and ferroptosis in muscle diseases and disorders: mechanisms and therapeutic prospects

The muscular system plays a critical role in the human body by governing skeletal movement, cardiovascular function, and the activities of digestive organs. Additionally, muscle tissues serve an endocrine function by secreting myogenic cytokines, thereby regulating metabolism throughout the entire body. Maintaining muscle function requires iron homeostasis. Recent studies suggest that disruptions in iron metabolism and ferroptosis, a form of iron-dependent cell death, are essential contributors to the progression of a wide range of muscle diseases and disorders, including sarcopenia, cardiomyopathy, and amyotrophic lateral sclerosis. Thus, a comprehensive overview of the mechanisms regulating iron metabolism and ferroptosis in these conditions is crucial for identifying potential therapeutic targets and developing new strategies for disease treatment and/or prevention. This review aims to summarize recent advances in understanding the molecular mechanisms underlying ferroptosis in the context of muscle injury, as well as associated muscle diseases and disorders. Moreover, we discuss potential targets within the ferroptosis pathway and possible strategies for managing muscle disorders. Finally, we shed new light on current limitations and future prospects for therapeutic interventions targeting ferroptosis.

Type 2 immunity in allergic diseases

Significant advancements have been made in understanding the cellular and molecular mechanisms of type 2 immunity in allergic diseases such as asthma, allergic rhinitis, chronic rhinosinusitis, eosinophilic esophagitis (EoE), food and drug allergies, and atopic dermatitis (AD). Type 2 immunity has evolved to protect against parasitic diseases and toxins, plays a role in the expulsion of parasites and larvae from inner tissues to the lumen and outside the body, maintains microbe-rich skin and mucosal epithelial barriers and counterbalances the type 1 immune response and its destructive effects. During the development of a type 2 immune response, an innate immune response initiates starting from epithelial cells and innate lymphoid cells (ILCs), including dendritic cells and macrophages, and translates to adaptive T and B-cell immunity, particularly IgE antibody production. Eosinophils, mast cells and basophils have effects on effector functions. Cytokines from ILC2s and CD4+ helper type 2 (Th2) cells, CD8 + T cells, and NK-T cells, along with myeloid cells, including IL-4, IL-5, IL-9, and IL-13, initiate and sustain allergic inflammation via T cell cells, eosinophils, and ILC2s; promote IgE class switching; and open the epithelial barrier. Epithelial cell activation, alarmin release and barrier dysfunction are key in the development of not only allergic diseases but also many other systemic diseases. Recent biologics targeting the pathways and effector functions of IL4/IL13, IL-5, and IgE have shown promising results for almost all ages, although some patients with severe allergic diseases do not respond to these therapies, highlighting the unmet need for a more detailed and personalized approach.

Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia

X-linked hypophosphataemia (XLH) is a rare metabolic bone disorder caused by pathogenic variants in the PHEX gene, which is predominantly expressed in osteoblasts, osteocytes and odontoblasts. XLH is characterized by increased synthesis of the bone-derived phosphaturic hormone fibroblast growth factor 23 (FGF23), which results in renal phosphate wasting with consecutive hypophosphataemia, rickets, osteomalacia, disproportionate short stature, oral manifestations, pseudofractures, craniosynostosis, enthesopathies and osteoarthritis. Patients with XLH should be provided with multidisciplinary care organized by a metabolic bone expert. Historically, these patients were treated with frequent doses of oral phosphate supplements and active vitamin D, which was of limited efficiency and associated with adverse effects. However, the management of XLH has evolved in the past few years owing to the availability of burosumab, a fully humanized monoclonal antibody that neutralizes circulating FGF23. Here, we provide updated clinical practice recommendations for the diagnosis and management of XLH to improve outcomes and quality of life in these patients.

Targeting of TAMs: can we be more clever than cancer cells?

With increasing incidence and geography, cancer is one of the leading causes of death, reduced quality of life and disability worldwide. Principal progress in the development of new anticancer therapies, in improving the efficiency of immunotherapeutic tools, and in the personification of conventional therapies needs to consider cancer-specific and patient-specific programming of innate immunity. Intratumoral TAMs and their precursors, resident macrophages and monocytes, are principal regulators of tumor progression and therapy resistance. Our review summarizes the accumulated evidence for the subpopulations of TAMs and their increasing number of biomarkers, indicating their predictive value for the clinical parameters of carcinogenesis and therapy resistance, with a focus on solid cancers of non-infectious etiology. We present the state-of-the-art knowledge about the tumor-supporting functions of TAMs at all stages of tumor progression and highlight biomarkers, recently identified by single-cell and spatial analytical methods, that discriminate between tumor-promoting and tumor-inhibiting TAMs, where both subtypes express a combination of prototype M1 and M2 genes. Our review focuses on novel mechanisms involved in the crosstalk among epigenetic, signaling, transcriptional and metabolic pathways in TAMs. Particular attention has been given to the recently identified link between cancer cell metabolism and the epigenetic programming of TAMs by histone lactylation, which can be responsible for the unlimited protumoral programming of TAMs. Finally, we explain how TAMs interfere with currently used anticancer therapeutics and summarize the most advanced data from clinical trials, which we divide into four categories: inhibition of TAM survival and differentiation, inhibition of monocyte/TAM recruitment into tumors, functional reprogramming of TAMs, and genetic enhancement of macrophages.

Probabilistic machine learning for battery health diagnostics and prognostics—review and perspectives

Diagnosing lithium-ion battery health and predicting future degradation is essential for driving design improvements in the laboratory and ensuring safe and reliable operation over a product’s expected lifetime. However, accurate battery health diagnostics and prognostics is challenging due to the unavoidable influence of cell-to-cell manufacturing variability and time-varying operating circumstances experienced in the field. Machine learning approaches informed by simulation, experiment, and field data show enormous promise to predict the evolution of battery health with use; however, until recently, the research community has focused on deterministic modeling methods, largely ignoring the cell-to-cell performance and aging variability inherent to all batteries. To truly make informed decisions regarding battery design in the lab or control strategies for the field, it is critical to characterize the uncertainty in a model’s predictions. After providing an overview of lithium-ion battery degradation, this paper reviews the current state-of-the-art probabilistic machine learning models for health diagnostics and prognostics. Details of the various methods, their advantages, and limitations are discussed in detail with a primary focus on probabilistic machine learning and uncertainty quantification. Last, future trends and opportunities for research and development are discussed.

Responses

Your email address will not be published. Required fields are marked *